Tower Bridge Advisors Has $2.49 Million Stock Holdings in Roche Holding AG (OTCMKTS:RHHBY)

Tower Bridge Advisors decreased its stake in shares of Roche Holding AG (OTCMKTS:RHHBY) by 3.2% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 70,619 shares of the company’s stock after selling 2,336 shares during the period. Tower Bridge Advisors’ holdings in Roche were worth $2,489,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of RHHBY. Altrius Capital Management Inc grew its holdings in Roche by 0.3% in the 4th quarter. Altrius Capital Management Inc now owns 183,448 shares of the company’s stock valued at $6,399,000 after buying an additional 603 shares in the last quarter. Verity Asset Management Inc. boosted its position in shares of Roche by 26.8% in the fourth quarter. Verity Asset Management Inc. now owns 8,036 shares of the company’s stock valued at $280,000 after acquiring an additional 1,697 shares during the period. Hantz Financial Services Inc. grew its stake in shares of Roche by 0.9% in the fourth quarter. Hantz Financial Services Inc. now owns 33,708 shares of the company’s stock valued at $1,176,000 after acquiring an additional 305 shares in the last quarter. Brooklyn Investment Group increased its position in Roche by 36.6% during the fourth quarter. Brooklyn Investment Group now owns 1,354 shares of the company’s stock worth $48,000 after acquiring an additional 363 shares during the period. Finally, Diversified Trust Co raised its stake in Roche by 1.2% in the 4th quarter. Diversified Trust Co now owns 60,453 shares of the company’s stock worth $2,130,000 after purchasing an additional 711 shares in the last quarter.

Roche Stock Up 0.7 %

Shares of Roche stock opened at $41.74 on Friday. The company has a current ratio of 1.26, a quick ratio of 0.97 and a debt-to-equity ratio of 0.86. Roche Holding AG has a 12-month low of $29.20 and a 12-month high of $42.43. The firm’s 50-day moving average price is $38.24 and its two-hundred day moving average price is $38.43.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on RHHBY. Sanford C. Bernstein upgraded shares of Roche to a “strong-buy” rating in a research report on Thursday, January 30th. UBS Group upgraded Roche from a “hold” rating to a “strong-buy” rating in a research note on Thursday, February 13th. Finally, Morgan Stanley started coverage on Roche in a research note on Wednesday, February 12th. They set an “equal weight” rating on the stock. Two analysts have rated the stock with a sell rating, two have given a hold rating, one has issued a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Roche currently has a consensus rating of “Hold”.

Roche Profile

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation.